File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Growth response during GnRH-A treatment in patients with precocious puberty

TitleGrowth response during GnRH-A treatment in patients with precocious puberty
Authors
Issue Date1996
PublisherMedcom Limited.
Citation
The 1st Joint Scientific Meeting of Hong Kong College of Paediatricians and Guangdong Pediatric Society of the Chinese Medical Association, Guangzhou, China, 25 May 1996. In Hong Kong Journal of Paediatrics, 1996, v.1 n. 2, p. 215 How to Cite?
AbstractAim To analyze the height gain in children with precocious puberty who have been treated with GnRH-A for at least three years. Method and Materials 18 patients (16 girls and 2 boys) with isosexual complete precocious puberty were included in the current study. Diagnosis was documented by LHRH stimulation test plus sex steroid assays. The mean age at onset of treatment was 6 years (SD = 2.41) and skeletal maturation was advanced (mean = 8.67, SD = 2.77 years). Hormonal profiles and skeletal maturation were monitored throughout the treatment course. Results The mean height SDS for age during the first 3 years of treatment followed the prepubertal reference values, but the height SDS based on skeletal maturation at the onset of treatment improved by 0.9 SDS during the three years of treatment (p<0.01). In a multiple regression analysis, height SDS and the advancement of skeletal maturation at the onset of treatment explained 41% of the growth response in the first 3 years. Neither the age at onset of treatment nor the midparental height improved the fit of the multiple regression By including the gain in skeletal maturation during the three treatment years a total of 77% of the variation in growth was explained Conclusion (1) GnRH-A has a beneficial effect on height prognosis in children with precocious puberty during the early years of treatment. (2) Height gain during the early treatment years can be partially predicted by the height SDS and skeletal age advancement at the onset of treatment.
Persistent Identifierhttp://hdl.handle.net/10722/105816
ISSN
2015 Impact Factor: 0.194
2015 SCImago Journal Rankings: 0.123

 

DC FieldValueLanguage
dc.contributor.authorCheung, PTen_HK
dc.contributor.authorKarlberg, JPEen_HK
dc.contributor.authorKwan, EYWen_HK
dc.contributor.authorLow, LCKen_HK
dc.date.accessioned2010-09-25T22:49:52Z-
dc.date.available2010-09-25T22:49:52Z-
dc.date.issued1996en_HK
dc.identifier.citationThe 1st Joint Scientific Meeting of Hong Kong College of Paediatricians and Guangdong Pediatric Society of the Chinese Medical Association, Guangzhou, China, 25 May 1996. In Hong Kong Journal of Paediatrics, 1996, v.1 n. 2, p. 215en_HK
dc.identifier.issn1013-9923en_HK
dc.identifier.urihttp://hdl.handle.net/10722/105816-
dc.description.abstractAim To analyze the height gain in children with precocious puberty who have been treated with GnRH-A for at least three years. Method and Materials 18 patients (16 girls and 2 boys) with isosexual complete precocious puberty were included in the current study. Diagnosis was documented by LHRH stimulation test plus sex steroid assays. The mean age at onset of treatment was 6 years (SD = 2.41) and skeletal maturation was advanced (mean = 8.67, SD = 2.77 years). Hormonal profiles and skeletal maturation were monitored throughout the treatment course. Results The mean height SDS for age during the first 3 years of treatment followed the prepubertal reference values, but the height SDS based on skeletal maturation at the onset of treatment improved by 0.9 SDS during the three years of treatment (p<0.01). In a multiple regression analysis, height SDS and the advancement of skeletal maturation at the onset of treatment explained 41% of the growth response in the first 3 years. Neither the age at onset of treatment nor the midparental height improved the fit of the multiple regression By including the gain in skeletal maturation during the three treatment years a total of 77% of the variation in growth was explained Conclusion (1) GnRH-A has a beneficial effect on height prognosis in children with precocious puberty during the early years of treatment. (2) Height gain during the early treatment years can be partially predicted by the height SDS and skeletal age advancement at the onset of treatment.-
dc.languageengen_HK
dc.publisherMedcom Limited.en_HK
dc.relation.ispartofHong Kong Journal of Paediatricsen_HK
dc.titleGrowth response during GnRH-A treatment in patients with precocious pubertyen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1013-9923&volume=1&spage=215&epage=&date=1996&atitle=Growth+response+during+Gn-RH-A+treatment+in+patients+with+precocious+pubertyen_HK
dc.identifier.emailCheung, PT: ptcheung@hkucc.hku.hken_HK
dc.identifier.emailKarlberg, JPE: jpekarl@hkucc.hku.hken_HK
dc.identifier.emailKwan, EYW: eywkwan@hkucc.hku.hken_HK
dc.identifier.emailLow, LCK: lcklow@hkucc.hku.hken_HK
dc.identifier.authorityCheung, PT=rp00351en_HK
dc.identifier.authorityKarlberg, JPE=rp00400en_HK
dc.identifier.authorityLow, LCK=rp00337en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros27050en_HK
dc.identifier.volume1en_HK
dc.identifier.spage215en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats